Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?  

While I am not aware of any evidence on the specific substitution of nab-paclitaxel for paclitaxel in the KEYNOTE-522 regimen, there is certainly data on the efficacy of nab-paclitaxel in the neoadjuvant setting in a variety of breast cancer subtypes, For example, in the ETNA trial (Gianni et al., P...